University news

By 2040, the energy demands of the tech industry could be up to 25 times higher than today, with unchecked growth of data centres driven by AI expected to create surges in electricity consumption that will strain power grids and accelerate carbon emissions.  

This is according to a new report from the University of Cambridge’s Minderoo Centre for Technology and Democracy, which suggests that even the most conservative estimate for big tech’s energy needs will see a five-fold increase over the next 15 years. 

The idea that governments such as the UK can become leaders in AI while simultaneously meeting their net zero targets amounts to “magical thinking at the highest levels,” according to the report’s authors. The UK is committed to net zero greenhouse gas emissions by 2050.

Researchers call for global standards in reporting AI’s environmental cost through forums such as COP, the UN climate summit, and argue that the UK should advocate for this on the international stage while ensuring democratic oversight at home.

The report, published today, synthesises projections from leading consultancies to forecast the energy demands of the global tech industry. The researchers note that these projections are based on claims by tech firms themselves. 

At the moment, data centres – the facilities that house servers for processing and storing data, along with cooling systems preventing this hardware from overheating – account for nearly 1.5% of global emissions.

This figure is expected to grow by 15-30% each year to reach 8% of total global greenhouse gas emissions by 2040, write the report’s authors. They point out that this would far exceed current emissions from air travel. 

The report highlights that in the US, China, and Europe, data centres already consume around 2-4% of national electricity, with regional concentrations becoming extreme. For example, up to 20% of all power in Ireland now goes to data centres in Dublin’s cluster.

“We know the environmental impact of AI will be formidable, but tech giants are deliberately vague about the energy requirements implicit in their aims,” said Bhargav Srinivasa Desikan, the report’s lead author from Cambridge’s Minderoo Centre.

“The lack of hard data on electricity and water consumption as well as associated carbon emissions of digital technology leaves policymakers and researchers in the dark about the climate harms AI might cause.”

“We need to see urgent action from governments to prevent AI from derailing climate goals, not just deferring to tech companies on the promise of economic growth,” said Desikan.

The researchers also use data from corporate press releases and ESG reports of some of the world’s tech giants to show the alarming trajectory of energy use before the AI race had fully kicked into gear.

Google’s reported greenhouse gas emissions rose by 48% between 2019 and 2023, while Microsoft’s reported emissions increased by nearly 30% from 2020 to 2023. Amazon’s carbon footprint grew around 40% between 2019 and 2021, and – while it has begun to fall – remains well above 2019 levels.

This self-reported data is contested, note the researchers, and some independent reporting suggests that actual emissions from tech companies are much higher.  

Several tech giants are looking to nuclear power to defuse the energy timebomb at the heart of their ambitions. Sam Altman, CEO of OpenAI, has argued that fusion is needed to meet AI’s potential, while Meta have said that nuclear energy can “provide firm, baseload power” to supply their data centres.

Microsoft have even signed a 20-year agreement to reactivate the Three Mile Island plant – site of the worst nuclear accident in US history.

Some tech leaders, such as former Google CEO Eric Schmidt, argue that environmental costs of AI will be offset by its benefits for the climate crisis – from contributing to scientific breakthroughs in green energy to enhanced climate change modelling.

“Despite the rapacious energy demands of AI, tech companies encourage governments to see these technologies as accelerators for the green transition,” said Prof Gina Neff, Executive Director of the Minderoo Centre for Technology and Democracy.

“These claims appeal to governments banking on AI to grow the economy, but they may compromise society's climate commitments.”

“Big Tech is blowing past their own climate goals, while they rely heavily on renewable energy certificates and carbon offsets rather than reducing their emissions,” said Prof Neff.

“Generative AI may be helpful for designing climate solutions, but there is a real risk that emissions from the AI build-out will outstrip any climate gains as tech companies abandon net zero goals and pursue huge AI-driven profits.”

The report calls for the UK’s environmental policies to be updated for the “AI era”. Recommendations include adding AI’s energy footprint into national decarbonisation plans, with specific carbon reduction targets for data centres and AI services, and requirements for detailed reporting of energy and water consumption.  

Ofgem should set strict energy efficiency targets for data centres, write the report’s authors, while the Department for Energy Security and Net Zero and the Department for Science, Innovation and Technology should tie AI research funding and data centre operations to clean power adoption.

The report’s authors note that that UK’s new AI Energy Council currently consists entirely of energy bodies and tech companies – with no representation for communities, climate groups or civil society.  

“Energy grids are already stretched,” said Prof John Naughton, Chair of the Advisory Board at the Minderoo Centre for Technology and Democracy.

“Every megawatt allocated to AI data centres will be a megawatt unavailable for housing or manufacturing. Governments need to be straight with the public about the inevitable energy trade-offs that will come with doubling down on AI as an engine of economic growth.”
 

With countries such as the UK declaring ambitious goals for both AI leadership and decarbonisation, a new report suggests that AI could drive a 25-fold increase in the global tech sector’s energy use by 2040.

halbergman/Getty Technicians walking through a vast data centre for AI and cloud computing in the US

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

A new study suggests that our ancestors’ close cohabitation with domesticated animals and large-scale migrations played a key role in the spread of infectious diseases.

The team, led by Professor Eske Willerslev at the Universities of Cambridge and Copenhagen, recovered ancient DNA from 214 known human pathogens in prehistoric humans from Eurasia.

They found that the earliest evidence of zoonotic diseases – illnesses transmitted from animals to humans, like COVID in recent times – dates back to around 6,500 years ago, with these diseases becoming more widespread approximately 5,000 years ago.

The study detected the world’s oldest genetic trace of the plague bacterium, Yersinia pestis, in a 5,500-year-old sample. The plague is estimated to have killed between one-quarter and one-half of Europe’s population during the Middle Ages.

In addition, the researchers found traces of many other diseases including:

Malaria (Plasmodium vivax) – 4,200 years ago

Leprosy (Mycobacterium leprae) – 1,400 years ago

Hepatitis B virus – 9,800 years ago

Diphtheria (Corynebacterium diphtheriae) – 11,100 years ago

This is the largest study to date on the history of infectious diseases and is published today in the journal Nature.

The researchers analysed DNA from over 1,300 prehistoric humans, some up to 37,000 years old. The ancient bones and teeth have provided a unique insight into the development of diseases caused by bacteria, viruses, and parasites.

“We’ve long suspected that the transition to farming and animal husbandry opened the door to a new era of disease – now DNA shows us that it happened at least 6,500 years ago,” said Willerslev.

He added: “These infections didn’t just cause illness – they may have contributed to population collapse, migration, and genetic adaptation.”

The significant increase in the incidence of zoonoses around 5,000 years ago coincides with a migration to north-western Europe from the Pontic Steppe – that is from parts of present-day Ukraine, south-western Russia and western Kazakhstan. The people embarking on this migration – and who to a large extent passed on the genetic profile found among people in north-western Europe today – belonged to the Yamnaya herders.

The findings could be significant for the development of vaccines and for understanding how diseases arise and mutate over time.

“If we understand what happened in the past, it can help us prepare for the future. Many of the newly emerging infectious diseases are predicted to originate from animals,” said Associate Professor Martin Sikora at the University of Copenhagen, and first author of the report.

Willerslev added: “Mutations that were successful in the past are likely to reappear. This knowledge is important for future vaccines, as it allows us to test whether current vaccines provide sufficient coverage or whether new ones need to be developed due to mutations.”

The sample material was primarily provided by museums in Europe and Asia. The samples were partly extracted from teeth, where the enamel acts as a lid that can protect the DNA against degradation as a result of the ravages of time. The rest of the DNA was primarily extracted from petrosa bones - the hardest bone in humans - located on the inside of the skull.

The research was funded by the Lundbeck Foundation.

Reference

Sikora, M. et al: ‘The spatiotemporal distribution of human pathogens in ancient Eurasia.’ Nature, July 2025. DOI: 10.1038/s41586-025-09192-8

Adapted from a press release by the University of Copenhagen.

Researchers have mapped the spread of infectious diseases in humans across millennia, to reveal how human-animal interactions permanently transformed our health today.

We’ve long suspected that the transition to farming and animal husbandry opened the door to a new era of disease – now DNA shows us that it happened at least 6,500 years agoEske WillerslevMarie Louise JørkovLate Neolithic skull from Madesø

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution-Noncommerical

During the French President's state visit to the United Kingdom, Institut Polytechnique de Paris (IP Paris), HEC Paris, Université Paris-Saclay, Oxford University and Cambridge University formalised a joint commitment to create a strategic partnership in the field of artificial intelligence.

Named the Entente CordIAle Paris-Saclay – Oxford-Cambridge AI Initiative, this partnership brings together two leading centres of scientific and technological excellence: the Saclay Cluster and the Universities of Oxford and Cambridge. They share a common ambition - to foster the emergence of excellent, ethical and sovereign artificial intelligence on a European scale.

The aim of the partnership is to structure long-term cooperation in AI research, training and innovation, in order to meet the major challenges of our time. It is organised around five key areas:

• Encouraging academic mobility between students, doctoral students, researchers and teachers to enhance expertise and training.
• Organising joint scientific events (seminars, workshops, symposia) on the major scientific and ethical challenges of AI.
• Launching collaborative research projects: co-direction of theses, interdisciplinary programmes, joint applications for funding.
• Involving industrial and innovation players, to accelerate technology transfer and support AI entrepreneurship.
• Strengthen bilateral cooperation, in line with national and European strategic priorities.

The 'Entente CordIAle Paris-Saclay – Oxford-Cambridge AI Initiative' extends the shared vision of Institut Polytechnique de Paris and HEC Paris: to establish a leading European hub in artificial intelligence, at the intersection of cutting-edge research, innovation, and the major challenges of our time.

A firmly solution-oriented ambition realized through Hi! PARIS, a key actor in the France 2030 strategy, integrating cutting-edge research, excellence in education, and concrete technological innovations to enhance European competitiveness. This interdisciplinary centre was co-founded by IP Paris and HEC Paris in 2020, joined by Inria in 2021, and benefits from €70 million in funding over five years.

In a joint statement, Thierry Coulhon, President of Institut Polytechnique de Paris and Eloïc Peyrache, Dean of HEC Paris, said:

"With the Entente CordIAle Paris-Saclay – Oxford-Cambridge AI Initiative, we are taking a decisive step forward in European scientific and academic cooperation. By bringing together the excellence of our institutions, through the interdisciplinary centre Hi! PARIS, with that of Oxford and Cambridge, we are laying the foundation for an unparalleled axis of research and innovation in artificial intelligence."

Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, concurred:

"The University of Cambridge is proud to be part of this collaboration, which reflects our deep commitment to shaping the future of AI through rigorous research, inclusive education, and responsible innovation. Combining our strengths and sharing knowledge will help us to address the most pressing challenges of our time and ensure AI serves the common good."

The Saclay Cluster, which includes Institut Polytechnique de Paris, HEC Paris and Université Paris-Saclay, the University of Oxford and the University of Cambridge, are joining  forces to build AI excellence.

Combining our strengths and sharing knowledge will help us to address the most pressing challenges of our time and ensure AI serves the common goodProfessor Deborah Prentice Partner signatories with Prof Deborah Prentice on the right

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

PFAS have been linked with a range of health issues including decreased fertility, developmental delays in children, and a higher risk of certain cancers and cardiovascular diseases.

Scientists at the University of Cambridge have identified a family of bacterial species, found naturally in the human gut, that absorb various PFAS molecules from their surroundings.  When nine of these bacterial species were introduced into the guts of mice to ‘humanise’ the mouse microbiome, the bacteria rapidly accumulated PFAS eaten by the mice - which were then excreted in faeces.

The researchers also found that as the mice were exposed to increasing levels of PFAS, the microbes worked harder, consistently removing the same percentage of the toxic chemicals. Within minutes of exposure, the bacterial species tested soaked up between 25% and 74% of the PFAS.

The results are the first evidence that our gut microbiome could play a helpful role in removing toxic PFAS chemicals from our body - although this has not yet been directly tested in humans.

The researchers plan to use their discovery to create probiotic dietary supplements that boost the levels of these helpful microbes in our gut, to protect against the toxic effects of PFAS.

The results are published today in the journal Nature Microbiology.

PFAS (Perfluoroalkyl and Polyfluoroalkyl Substances) can’t be avoided in our modern world. These man-made chemicals are in many everyday items including waterproof clothing, non-stick pans, lipsticks and food packaging, used for their resistance to heat, water, oil and grease. But because they take thousands of years to break down, they are accumulating in large quantities in the environment – and in our bodies.

Dr Kiran Patil, in the University of Cambridge’s MRC Toxicology Unit and senior author of the report, said: “Given the scale of the problem of PFAS ‘forever chemicals’, particularly their effects on human health, it’s concerning that so little is being done about removing these from our bodies.”

“We found that certain species of human gut bacteria have a remarkably high capacity to soak up PFAS from their environment at a range of concentrations, and store these in clumps inside their cells. Due to aggregation of PFAS in these clumps, the bacteria themselves seem protected from the toxic effects.”

Dr Indra Roux, a researcher at the University of Cambridge’s MRC Toxicology Unit and a co-author of the study said: “The reality is that PFAS are already in the environment and in our bodies, and we need to try and mitigate their impact on our health now. We haven’t found a way to destroy PFAS, but our findings open the possibility of developing ways to get them out of our bodies where they do the most harm.”

There is increasing concern about the environmental and health impacts of PFAS, and in April 2025 the UK launched a parliamentary inquiry into their risks and regulation.

There are over 4,700 PFAS chemicals in widespread use. Some get cleared out of the body in our urine in a matter of days, but others with a longer molecular structure can hang around in the body for years.

Dr Anna Lindell, a researcher at the University of Cambridge’s MRC Toxicology Unit and first author of the study said: “We’re all being exposed to PFAS through our water and food – these chemicals are so widespread that they’re in all of us.

“PFAS were once considered safe, but it’s now clear that they’re not. It’s taken a long time for PFAS to become noticed because at low levels they’re not acutely toxic. But they’re like a slow poison.”

Lindell and Patil have co-founded a startup, Cambiotics, with serial entrepreneur Peter Holme Jensen to develop probiotics that remove PFAS from the body, and they are investigating various ways of turbo-charging the microbes’ performance. Cambiotics is supported by Cambridge Enterprise, the innovation arm of the University of Cambridge, which helps researchers translate their work into globally-leading economic and social impact.

While we wait for new probiotics to become available, the researchers say the best things we can do to help protect ourselves against PFAS are to avoid PFAS-coated cooking pans, and use a good water filter.

The research was funded primarily by the Medical Research Council, National Institute for Health Research, and Wellcome.

Reference 

Lindell, A.E.: ‘Human gut bacteria bioaccumulate per- and polyfluoroalkyl substances.’ Nature Microbiology, July 2025. DOI: 10.1038/s41564-025-02032-5

Scientists have discovered that certain species of microbe found in the human gut can absorb PFAS - the toxic and long-lasting ‘forever chemicals.’ They say boosting these species in our gut microbiome could help protect us from the harmful effects of PFAS.

“Given the scale of the problem of PFAS ‘forever chemicals’, particularly their effects on human health, it’s concerning that so little is being done about removing these from our bodies.”Kiran PatilPeter Northrop / MRC Toxicology UnitPFAS accumulation in gut bacteria

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution-Noncommerical

Organised by the University Sports service, the annual ceremony brought together students, staff, alumni, and guests to recognise the exceptional contributions and successes of sports clubs, teams, and individuals across the University.

Hosted by Director of Sport Mark Brian, the awards were presented by a distinguished line-up of guests including Professor Bhaskar Vira (Pro-Vice-Chancellor for Education and Chair of the Sports Committee), Deborah Griffin (incoming RFU President), Scott Annett (CURUFC Director of Rugby), and Senior Tutors and Committee Members Victoria Harvey and Dr Jane Greatorex. Former Sports Personality of the Year Jack Murphy returned to present one of the evening’s headline awards.

The awards shine a light on the importance of sport as part of the Cambridge experience - enhancing student wellbeing, building community, and nurturing excellence both on and off the field. The winners were selected by a panel of senior University staff, with the exception of the Sporting Moment of the Year, which was decided by public vote.

This year’s winners:

Club of the Year: Association Football Club

Team of the Year: Women’s Cross Country A Team, Hare & Hounds

Sports Person of the Year: Jan Helmich (Trinity Hall), Rowing

Unsung Hero: Emma Paterson (Gonville and Caius), Mixed Lacrosse

Sports Club Personality of the Year: Tads Ciecieski-Holmes (Wolfson), Modern Pentathlon

Sporting Moment of the Year: Men’s Volleyball Blues Varsity Set Point

Newcomer of the Year: Lauren Airey (Emmanuel), Modern Pentathlon

College Team of the Year: Downing Table Tennis

Outstanding Contribution Awards were presented to:

• Lucy Xu (Pembroke), Taekwondo
• Sam Grimshaw (Girton), Hockey
• Georgina Quayle (Homerton), Modern Pentathlon and Swimming & Water Polo
• Ben Rhodes (Jesus), Touch Rugby
• Izzy Howse (Robinson), Netball
• Ksenija Belada (Peterhouse), Volleyball
• Izzy Winter and Jess Reeve, Clarissa’s Campaign for Cambridge Hearts

A particularly moving moment came during the presentation of an Outstanding Contribution Award to Clarissa’s Campaign for Cambridge Hearts, recognising efforts by Izzy Winter and Jess Reeve to raise funds and awareness for student heart screenings. For more information on the October 2025 screenings, visit www.sport.cam.ac.uk/heart-screening.

The University extends its congratulations to all nominees and winners, and its thanks to everyone who participated in and supported the 2025 Sports Awards. The event was a testament to the passion, resilience, and camaraderie that sport brings to the Cambridge community.

To read more about all the nominees, please visit the Sports Awards page: https://www.sport.cam.ac.uk/sportsawards/sports-awards-2025

Story by: Will Galpin

Crowds cheer on the Sports Awards 2025

Crowds cheer on the nominees and winners at the 2025 Sports Awards.

The University of Cambridge recently celebrated a remarkable year of student sporting achievement at the 2025 Cambridge University Sports Awards.

Dik Ng Winners of the Cambridge Sports Awards 2025 gathered together

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution

As the world’s most intensive science and technology cluster, Cambridge is driving breakthrough research and attracting global investment across quantum, life sciences, and biotech.

During his visit, hosted by Founders at University of Cambridge and Innovate Cambridge, the Ambassador heard about the University’s success in securing funding for these critical areas and its bold plans to fuel national economic growth—most notably through the National Innovation Hub and the West Cambridge Innovation District, set to become Europe’s leading centre for AI, quantum, and climate research.

At the heart of the visit was a tour of the new Ray Dolby Centre, home to the historic Cavendish Laboratory. Hosted by Professor Mete Atatüre, Head of the Department of Physics, Lord Mandelson learned about Cambridge’s leadership in quantum technologies and the rapidly growing portfolio of real-world applications emerging from this research.

Vice-Chancellor Professor Deborah Prentice then hosted a roundtable lunch at Cambridge Enterprise, the University’s commercialisation arm, where leaders from high-growth companies in quantum, AI, and life sciences joined to discuss opportunities for deepening UK-US tech collaboration.

The visit follows the recent signing of the UK-US trade agreement, which lays the groundwork for a future technology partnership between the two countries. As both nations turn to innovation as a key driver of economic growth and global problem-solving, Cambridge stands ready to play a pivotal role.

Recent Dealroom research for Founders at the University of Cambridge highlights Cambridge’s momentum: the area now attracts more venture capital investment in deep tech per capita than anywhere else globally. The region’s tech ecosystem is valued at $222 billion—18% of the UK’s total tech value, second only to London.

Prof Deborah Prentice said: "It was a pleasure to join the Ambassador and colleagues to showcase the full depth and breadth of Cambridge’s research and business strengths - from personalised vaccines and genomics to qubits and semiconductors. Cambridge has unique capabilities to help drive the UK-US tech partnership forward, and we’re excited to build on this momentum."

This week, UK Ambassador to the United States of America Lord Mandelson visited the University of Cambridge to explore its world-leading strengths in innovation and its deepening academic and industrial partnerships with the USA.

Cambridge has unique capabilities to help drive the UK-US tech partnership forward, and we’re excited to build on this momentum.Vice-Chancellor, Professor Deborah PrenticeDomininkas PhotographyLord Mandelson and Professor Deborah Prentice with the Cambridge Enterprise team.

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Mary Catchpole, 19, was given a newly licensed drug called leniolisib (or Joenja) at Addenbrooke’s Hospital in Cambridge. It is the first ever targeted treatment for a rare, inherited immunodeficiency called Activated PI3-Kinase delta syndrome (APDS).

People with APDS have a weakened immune system, making them vulnerable to repeated infections and autoimmune or inflammatory conditions. Discovered just over a decade ago by a team of Cambridge researchers, it is a debilitating and life-threatening condition, with patients more likely to develop blood cancers like lymphoma.

APDS is a relatively new immuno-deficiency, with Mary’s family playing a key role in its discovery in 2013. Mary’s mother and uncle, who were Addenbrooke’s patients, were offered DNA sequencing (whole exome sequencing) to see if there was a genetic cause for their immuno-deficiency.

Cambridge researchers identified a change in their genes that increased activity of an enzyme called PI3-Kinase delta, resulting in the illness being named Activated PI3-Kinase delta syndrome (APDS).

The team, which involved researchers from the University of Cambridge, Babraham Institute, MRC Laboratory for Molecular Biology, and clinicians from Addenbrooke’s, was primarily funded by Wellcome and the National Institute for Health and Care Research (NIHR).

With APDS, the enzyme PI3-Kinase delta is “switched on” all the time, preventing immune cells from fighting infection and leads to abnormal or dysregulated immune function.

The new treatment – with one tablet taken twice a day – aims to inhibit the enzyme, effectively normalising the immune system.

Dr Anita Chandra, consultant immunologist at Addenbrooke’s and Affiliated Assistant Professor at the University of Cambridge, said: “It is incredible to go from the discovery of a new disease in Cambridge to a treatment being approved and offered on the NHS, within the space of 12 years.

“This new drug will make a huge difference to people living with APDS, hopefully allowing patients to avoid antibiotics, immunoglobulin replacement and potentially even a stem cell transplant in the future.”

Professor Sergey Nejentsev from the University of Cambridge who led the research that discovered APDS said: “As soon as we understood the cause of APDS, we immediately realised that certain drugs could be used to inhibit the enzyme that is activated in these patients. Leniolisib does precisely that. I am delighted that we finally have a treatment which will change the lives of APDS patients.”

The disorder has significantly impacted Mary’s family on her mother’s side. Her aunt died aged 12, while her mother, uncle and grandmother all died in their 30s and 40s.

Mary works as a teaching assistant and lives in Great Yarmouth, Norfolk with her father Jimmy and older brother Joe, who does not have the condition.

Prior to leniolisib, the only treatments available to APDS patients include antibiotics for infections, immunoglobulin replacement therapy (to prevent infections and damage to organs) or a bone marrow or stem cell transplant, which can be a potential cure but carries significant risks.

Mary said: “Having APDS means I’ve got a higher chance of infections and getting unwell, which is hard when all I want to do is work and dance and have adventures. All my life I’ve had to have weekly infusions which make me feel like a pin cushion, and I’ve had to take lots of medication which has been tough.

“Now that I have this new treatment, it does feel bitter-sweet as my late mum and other affected members of my family never got the chance to have this new lease of life, but it is a gift. I feel blessed.”

Leniolisib was licensed for use in America in 2023, following clinical trials. After assessment and approval by the UK medicines regulator, the MHRA, it is now approved by NICE (National Institute for Health and Care Excellence) for NHS use - the first health system in Europe to use it to treat patients with APDS.

Professor James Palmer, NHS England’s Medical Director for Specialised Commissioning, said: “We’re delighted to see Mary become the first patient in Europe to receive this first-ever targeted and approved therapy for a rare condition identified just over a decade ago – in Cambridge no less.

“This treatment could be life-changing for those affected by this debilitating genetic disorder, and this important step forward is another example of the NHS’s commitment to offering access to innovative medicines for those living with rare conditions.”

As a tertiary centre for immune-deficiencies, patients eligible for leniolisib can be referred to Addenbrooke’s, part of Cambridge University Hospitals NHS Foundation Trust, for specialist review and care and ongoing research in this rare condition.

Dr Susan Walsh, Chief Executive Officer at Immunodeficiency UK, said: “With leniolisib, we now have a targeted treatment available that addresses the fundamental cause of the immune system problems experienced in APDS. This demonstrates the power of research and is a huge leap forward. The new treatment will help improve the quality of life for those families living with APDS.”

By looking at the role of the enzyme linked to APDS and the impact of the new targeted drug on the patient’s immune system, it is hoped there is potential for leniolisib to be applied to other more common immune related conditions in the future.

Adapted from a press release from Cambridge University Hospitals.

A teenager who has lost family members including her mother because of a rare genetic hereditary illness has become the first patient in the UK and Europe to have a new treatment developed by Cambridge researchers and approved for use on the NHS.

It is incredible to go from the discovery of a new disease in Cambridge to a treatment being approved and offered on the NHS, within the space of 12 yearsAnita ChandraCambridge University HospitalsMary Catchpole and Anita Chandra

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution

Mary Catchpole, 19, was given a newly licensed drug called leniolisib (or Joenja) at Addenbrooke’s Hospital in Cambridge. It is the first ever targeted treatment for a rare, inherited immunodeficiency called Activated PI3-Kinase delta syndrome (APDS).

People with APDS have a weakened immune system, making them vulnerable to repeated infections and autoimmune or inflammatory conditions. Discovered just over a decade ago by a team of Cambridge researchers, it is a debilitating and life-threatening condition, with patients more likely to develop blood cancers like lymphoma.

APDS is a relatively new immuno-deficiency, with Mary’s family playing a key role in its discovery in 2013. Mary’s mother and uncle, who were Addenbrooke’s patients, were offered DNA sequencing (whole exome sequencing) to see if there was a genetic cause for their immuno-deficiency.

Cambridge researchers identified a change in their genes that increased activity of an enzyme called PI3-Kinase delta, resulting in the illness being named Activated PI3-Kinase delta syndrome (APDS).

The team, which involved researchers from the University of Cambridge, Babraham Institute, MRC Laboratory for Molecular Biology, and clinicians from Addenbrooke’s, was primarily funded by Wellcome and the National Institute for Health and Care Research (NIHR).

With APDS, the enzyme PI3-Kinase delta is “switched on” all the time, preventing immune cells from fighting infection and leads to abnormal or dysregulated immune function.

The new treatment – with one tablet taken twice a day – aims to inhibit the enzyme, effectively normalising the immune system.

Dr Anita Chandra, consultant immunologist at Addenbrooke’s and Affiliated Assistant Professor at the University of Cambridge, said: “It is incredible to go from the discovery of a new disease in Cambridge to a treatment being approved and offered on the NHS, within the space of 12 years.

“This new drug will make a huge difference to people living with APDS, hopefully allowing patients to avoid antibiotics, immunoglobulin replacement and potentially even a stem cell transplant in the future.”

Professor Sergey Nejentsev from the University of Cambridge who led the research that discovered APDS said: “As soon as we understood the cause of APDS, we immediately realised that certain drugs could be used to inhibit the enzyme that is activated in these patients. Leniolisib does precisely that. I am delighted that we finally have a treatment which will change the lives of APDS patients.”

The disorder has significantly impacted Mary’s family on her mother’s side. Her aunt died aged 12, while her mother, uncle and grandmother all died in their 30s and 40s.

Mary works as a teaching assistant and lives in Great Yarmouth, Norfolk with her father Jimmy and older brother Joe, who does not have the condition.

Prior to leniolisib, the only treatments available to APDS patients include antibiotics for infections, immunoglobulin replacement therapy (to prevent infections and damage to organs) or a bone marrow or stem cell transplant, which can be a potential cure but carries significant risks.

Mary said: “Having APDS means I’ve got a higher chance of infections and getting unwell, which is hard when all I want to do is work and dance and have adventures. All my life I’ve had to have weekly infusions which make me feel like a pin cushion, and I’ve had to take lots of medication which has been tough.

“Now that I have this new treatment, it does feel bitter-sweet as my late mum and other affected members of my family never got the chance to have this new lease of life, but it is a gift. I feel blessed.”

Leniolisib was licensed for use in America in 2023, following clinical trials. After assessment and approval by the UK medicines regulator, the MHRA, it is now approved by NICE (National Institute for Health and Care Excellence) for NHS use - the first health system in Europe to use it to treat patients with APDS.

Professor James Palmer, NHS England’s Medical Director for Specialised Commissioning, said: “We’re delighted to see Mary become the first patient in Europe to receive this first-ever targeted and approved therapy for a rare condition identified just over a decade ago – in Cambridge no less.

“This treatment could be life-changing for those affected by this debilitating genetic disorder, and this important step forward is another example of the NHS’s commitment to offering access to innovative medicines for those living with rare conditions.”

As a tertiary centre for immune-deficiencies, patients eligible for leniolisib can be referred to Addenbrooke’s, part of Cambridge University Hospitals NHS Foundation Trust, for specialist review and care and ongoing research in this rare condition.

Dr Susan Walsh, Chief Executive Officer at Immunodeficiency UK, said: “With leniolisib, we now have a targeted treatment available that addresses the fundamental cause of the immune system problems experienced in APDS. This demonstrates the power of research and is a huge leap forward. The new treatment will help improve the quality of life for those families living with APDS.”

By looking at the role of the enzyme linked to APDS and the impact of the new targeted drug on the patient’s immune system, it is hoped there is potential for leniolisib to be applied to other more common immune related conditions in the future.

Adapted from a press release from Cambridge University Hospitals.

A teenager who has lost family members including her mother because of a rare genetic hereditary illness has become the first patient in the UK and Europe to have a new treatment developed by Cambridge researchers and approved for use on the NHS.

It is incredible to go from the discovery of a new disease in Cambridge to a treatment being approved and offered on the NHS, within the space of 12 yearsAnita Chandra

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Wayve is one of the UK’s most valuable deep tech startups, backed by more than $1 billion in funding.  Alex Kendall co-founded the company in 2017 following his PhD at the University of Cambridge, where he pioneered a contrarian approach to self-driving cars.  

At a time when the industry relied heavily on rule-based systems, maps and multiple sensors, he proposed a different vision powered by deep learning—where a single neural network could learn to drive from raw data without human intervention. 

Wayve’s approach creates a general-purpose driving intelligence that can adapt to new environments. Its models are trained on tens of petabytes of real-world data from its team of safety drivers. Wayve tests its models in both real-world driving settings and in simulation. Real-world testing exposes AI to diverse conditions, while simulation enables efficient, large-scale validation. 

Synthetic data on rare or unseen scenarios are used to train their technology to safely navigate the real world. Wayve tests these safety-critical scenarios, such as near collisions or unpredictable pedestrian behaviour, using a cutting-edge generative world model.

Wayve’s autonomous cars have been navigating the complex streets of London since 2019, overseen by legally required safety drivers. Last year they expanded to San Francisco and have also been testing these cars in Stuttgart, and Japan. The company plans to license its technology to car manufacturers, with Nissan set to integrate Wayve’s AI to support driver assistance into its vehicles by 2027. 

The engineering team have also built the first language-driving model tested on public roads. LINGO opens up communication with the robot and can narrate its driving and answer questions. That means Wayve’s engineers (and eventually passengers) can communicate with the AI and ask it to explain decisions or drive in a certain way.  

He sees autonomous driving as a launchpad for a broader revolution in embodied AI, with applications in robotics, manufacturing, and healthcare. “Bringing AI into the physical world in a way that it can interact with us, is real – is tangible,” explains Kendall, “I think it’s going to be the biggest transformation we go through in our lifetimes.”  

Adapted from a Royal Academy of Engineering press release: 

Alex Kendall, CEO and Co-Founder of Wayve, a billion-dollar UK company that uses deep learning to solve the challenges of self-driving cars, has been presented with the Princess Royal Silver Medal, one of the Royal Academy of Engineering’s most prestigious individual awards. 

WayveWayve autonomous car

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution

At a reception at the Vice-Chancellor’s Lodge this week, which celebrated his service to the University, Lord Sainsbury talked fondly about his own time as a student at Cambridge, and said: “It has been a great honour and pleasure to be Chancellor of the University of Cambridge, one of the world’s greatest universities.

“Over the years, I have watched with awe how the University has produced an endless stream of brilliant research and an enlightened education for its undergraduates and postgraduates, and I hope that by being Chancellor, and in a number of other ways, I have to some extent repaid my debt to the University. I will always look back at my time as Chancellor with the greatest pleasure.”

The Vice-Chancellor, Professor Deborah Prentice, paid a warm tribute to the Chancellor and thanked him for his service and contribution to the life of the University, and his support for her.

In a recent edition of CAM – the University's alumni magazine – other friends and former colleagues recounted the unique qualities Lord Sainsbury has brought to the post during almost a decade and a half of unwavering commitment.

With high-level experience in government and industry alike, Lord Sainsbury has been a highly effective advocate for the best interests of the University on both the national and global stage. “He’s a man of great ability and thoughtfulness,” says Professor Mike Proctor, 2013-2023 Provost of King’s College, Lord Sainsbury’s alma mater. “He’s very well connected in both the public and private sectors. And that’s been very helpful to the University at large.” 

Professor Stephen Toope, the 346th Vice-Chancellor, says that although the role is technically ceremonial, Lord Sainsbury was always willing to go above and beyond. “If I asked him to do something for the University – connect me with the right person, give me a piece of advice – he always did it. He was very generous in making introductions, and saw his role as trying to strengthen the University where he could. And that was largely by supporting the people who’d been asked to do the big jobs – on the Council and in the leadership of Cambridge.”

As a former Minister of Science and Innovation, Lord Sainsbury has brought a wealth of experience to the University. But he has also brought his own love of research and innovation to bear, as Rebecca Simmons, the VC’s former Chief of Staff and now COO of quantum computing company Riverlane, saw first-hand. “He liked to get into the detail beforehand, so he could make good connections with people,” she remembers. “And sometimes, he would come back to see the same people over several years. For example, he stayed in touch with the CEO of Endomag, a cancer diagnostics spinout, and made a point of going back to meet them at key moments. In fact, accompanying him on visits was one of the most fun parts of my job.” 

Dr Regina Sachers, former Head of the Vice-Chancellor’s Office and now Director of Governance and Compliance, agrees. “He found it easy to connect with academics because he was genuinely interested in the work. He would always ask very informed questions, and would frequently offer his card and put people in touch with his own connections. It felt like a very genuine and low-key approach.”

The role of Vice-Chancellor can be lonely, says Sir Leszek Borysiewicz, Vice-Chancellor 2010-17: often, the only person you can talk to is the Chancellor. “And Lord Sainsbury always made himself available. He was a friend, a mentor, an adviser. We had differences of opinion, but we could always talk. Having that open debate meant you could road-test the strength of an argument – and, sometimes, backpedal, because he’d made some very valid points that were critical for the University. And I can attest that during my time as Vice-Chancellor, he was always there for the difficult issues. He was quiet and understated, but very thoughtful and very wise – and never interfered with the executive functions that the Vice-Chancellor has to exercise.”

“Lord Sainsbury does not have an agenda of his own: he seeks to do what the University needs, and always has its best interests at heart,” says current Vice-Chancellor Professor Deborah Prentice. “He approaches the job with selflessness and the mentality of a public servant. I like the fact that sometimes he just turns up to things; he’s such a curious and interested person. I think he very much embodies the values of the University.” 

Professor Toope says that he has always been struck by Lord Sainsbury’s “complete lack of pomposity. Some people think they are the role. He always understood that the role is the role: he just happened to be occupying it for a period. And he brought a personal and political integrity to it.”

The election for Lord Sainsbury’s successor as Chancellor takes place next month.

Read about the election of a Chancellor at the University.

After 14 years as Chancellor of the University, Lord Sainsbury of Turville has formally stood down from the role.

I will always look back at my time as Chancellor with the greatest pleasure.Lord Sainsbury of Turville

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

So say a team of researchers who have uncovered significant weaknesses in two of the art protection tools most used by artists to safeguard their work.

According to their creators, Glaze and NightShade were both developed to protect human creatives against the invasive uses of generative artificial intelligence.

The tools are popular with digital artists who want to stop artificial intelligence models (like the AI art generator Stable Diffusion) from copying their unique styles without consent. Together, Glaze and NightShade have been downloaded almost nine million times.

But according to an international group of researchers, these tools have critical weaknesses that mean they cannot reliably stop AI models from training on artists’ work.

The tools add subtle, invisible distortions (known as poisoning perturbations) to digital images. These ‘poisons’ are designed to confuse AI models during training. Glaze takes a passive approach, hindering the AI model’s ability to extract key stylistic features. NightShade goes further, actively corrupting the learning process by causing the AI model to associate an artist’s style with unrelated concepts.

But the researchers have created a method – called LightShed – that can bypass these protections. LightShed can detect, reverse-engineer and remove these distortions, effectively stripping away the poisons and rendering the images usable again for Generative AI model training.

It was developed by researchers at the University of Cambridge along with colleagues at the Technical University Darmstadt and the University of Texas at San Antonio. The researchers hope that by publicising their work – which will be presented at the USENIX Security Symposium, a major security conference, in August – they can let creatives know that there are major issues with art protection tools.

LightShed works through a three-step process. It first identifies whether an image has been altered with known poisoning techniques.

In a second, reverse engineering step, it learns the characteristics of the perturbations using publicly available poisoned examples. Finally, it eliminates the poison to restore the image to its original, unprotected form.

In experimental evaluations, LightShed detected NightShade-protected images with 99.98% accuracy and effectively removed the embedded protections from those images.

“This shows that even when using tools like NightShade, artists are still at risk of their work being used for training AI models without their consent,” said first author Hanna Foerster from Cambridge’s Department of Computer Science and Technology, who conducted the work during an internship at TU Darmstadt.

Although LightShed reveals serious vulnerabilities in art protection tools, the researchers stress that it was developed not as an attack on them – but rather an urgent call to action to produce better, more adaptive ones.

“We see this as a chance to co-evolve defenses,” said co-author Professor Ahmad-Reza Sadeghi from the Technical University of Darmstadt. “Our goal is to collaborate with other scientists in this field and support the artistic community in developing tools that can withstand advanced adversaries.”

The landscape of AI and digital creativity is rapidly evolving. In March this year, OpenAI rolled out a ChatGPT image model that could instantly produce artwork in the style of Studio Ghibli, the Japanese animation studio.

This sparked a wide range of viral memes – and equally wide discussions about image copyright, in which legal analysts noted that Studio Ghibli would be limited in how it could respond to this since copyright law protects specific expression, not a specific artistic ‘style’.  

Following these discussions, OpenAI announced prompt safeguards to block some user requests to generate images in the styles of living artists.  

But issues over generative AI and copyright are ongoing, as highlighted by the copyright and trademark infringement case currently being heard in London’s high court.

Global photography agency Getty Images is alleging that London-based AI company Stability AI trained its image generation model on the agency’s huge archive of copyrighted pictures. Stability AI is fighting Getty’s claim and arguing that the case represents an “overt threat” to the generative AI industry.

And earlier this month, Disney and Universal announced they are suing AI firm Midjourney over its image generator, which the two companies said is a “bottomless pit of plagiarism.”

“What we hope to do with our work is to highlight the urgent need for a roadmap towards more resilient, artist-centred protection strategies,” said Foerster. “We must let creatives know that they are still at risk and collaborate with others to develop better art protection tools in future.”

Hanna Foerster is a member of Darwin College, Cambridge. 

Reference:
Hanna Foerster et al. ‘LightShed: Defeating Perturbation-based Image Copyright Protections.’ Paper presented at the 34th USENIX Security Symposium. https://www.usenix.org/conference/usenixsecurity25/presentation/foerster

Artists urgently need stronger defences to protect their work from being used to train AI models without their consent.  

Even when using tools like NightShade, artists are still at risk of their work being used for training AI models without their consentHanna FoersterAnastasia Babenko via Getty ImagesArtist at work

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

A 15-seater autonomous bus will operate between Madingley Road Park & Ride, and around the University's Eddington neighbourhood and Cambridge West Innovation District. 

The early phase of the trial, following extensive virtual and on-road testing, starts on Tuesday 24 June with a limited number of morning and afternoon runs each Monday-Friday.

The trial passenger service is free and will enhance local connections, improving access to places of work and study, as well as community and sports facilities for those living and working in the area.

Dan Clarke, Head of Innovation and Technology at the Greater Cambridge Partnership, said: "This is an exciting milestone, but it’s just the beginning. People may have already seen the bus going around Eddington and Cambridge West from Madingley Park & Ride recently, as, after the extensive on-track training with the drivers, we’ve been running the bus on the road without passengers to learn more about how other road-users interact with the technology. We’re now moving gradually to the next stage of this trial by inviting passengers to use Connector.

"As with all new things, our aim is to introduce this new technology in a phased way that balances the trialling of these new systems with safety and the passenger experience. This will ensure we can learn more about this technology and showcase the potential for self-driving vehicles to support sustainable, reliable public transport across Cambridge."

Connector begins trial phase Connector begins trial phase Video of Connector begins trial phase */

The vehicle is operated by Whippet Coaches using autonomous technology from Fusion Processing. 

Professor Anna Philpott, Pro-Vice-Chancellor for Resources and Operations at the University of Cambridge, said "Innovation and research that contributes to society is at the heart of the University’s mission, and this trial aligns with our vision for sustainable and pioneering transport solutions for everyone travelling to and from our sites. Cambridge West Innovation District and Eddington are fitting locations for such an ambitious and forward-thinking project."

A full-scale launch of two full-size autonomous buses on a second route to the Cambridge Biomedical Campus will begin later this year.

The Connector trial is part of a national Centre for Connected and Autonomous Vehicles (CCAV) programme backed by the UK Government to explore how autonomous buses can be safely and effectively integrated into public transport systems.

All vehicles are supported by trained safety drivers at all times and have already undergone digital simulation and rigorous on-road testing.

The Greater Cambridge Partnership’s Connector project is bringing self-driving passenger transport to the city.

Cambridge West Innovation District and Eddington are fitting locations for such an ambitious and forward-thinking project.Professor Anna Philpott, Pro-Vice-Chancellor for Resources and Operations Teams from the Greater Cambridge Partnership and Cambridge University with the autonomous bus.

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

The Rubin Observatory, jointly funded by the US National Science Foundation and the US Department of Energy’s Office of Science, has released its first imagery, showing cosmic phenomena at an unprecedented scale.

In just over 10 hours of test observations, the NSF-DOE Rubin Observatory has already captured millions of galaxies and Milky Way stars and thousands of asteroids. The imagery is a small preview of the Rubin Observatory’s upcoming 10-year scientific mission to explore and understand some of the universe's biggest mysteries.

Located on a mountaintop in Chile, the Rubin Observatory will repeatedly scan the sky for 10 years and create an ultra-wide, ultra-high-definition time-lapse record of our universe. The region in central Chile is favoured for astronomical observations because of its dry air and dark skies, and allows for an ideal view of the Milky Way’s centre.

The facility is set to achieve ‘first light,’ or make the first scientific observations of the Southern Hemisphere’s sky using its 8.4-meter Simonyi Survey Telescope, on 4 July.

UK astronomers, including from the University of Cambridge, are celebrating their role in the most ambitious sky survey to date.

“We will be looking at the universe in a way that we have never done before, and this exploration is bound to throw up surprises that we never imagined,” said Professor Hiranya Peiris from Cambridge’s Institute of Astronomy, and a builder of the Legacy Survey of Space and Time (LSST) Dark Energy Science Collaboration. 

Enabled by an investment of £23 million from the Science and Technology Facilities Council (STFC), UK astronomers and software developers have been preparing the hardware and software needed to analyse the petabytes of data that the survey will produce to enable groundbreaking science that will enhance our understanding of the universe.

The UK is the second largest international contributor to the multinational project, putting UK astronomers at the forefront when it comes to exploiting this unique window on the Universe.

The UK is also playing a significant role in the management and processing of the unprecedented amounts of data. The UK will host one of three international data facilities and process around 1.5 million images, capturing around 10 billion stars and galaxies. When complete, the full 10-year survey is expected to rack up 500 petabytes of date – the same storage as half-a-million 4K Hollywood movies.

The UK’s science portal for the international community is capable of connecting around 1,500 astronomers with UK Digital Research Infrastructure to support the exploitation of this uniquely rich and detailed view of the Universe.

More than two decades in the making, Rubin is the first of its kind: its mirror design, camera size and sensitivity, telescope speed, and computing infrastructure are each in an entirely new category. Over the next 10 years, Rubin will perform the Legacy Survey of Space and Time (LSST) using the LSST Camera and the Simonyi Survey Telescope.

By repeatedly scanning the sky for 10 years, the observatory will deliver a treasure trove of discoveries: asteroids and comets, pulsating stars, and supernova explosions. Science operations are expected to start towards the end of 2025.

"I can’t wait to explore the first LSST catalogues - revealing the faintest dwarf galaxies and stellar streams swarming through the Milky Way’s halo," said Professor Vasily Belokurov from Cambridge's Institute of Astronomy, member of LSST:UK. "A new era of galactic archaeology is beginning!”

“UK researchers have been contributing to the scientific and technical preparation for the Rubin LSST for more than ten years,” said Professor Bob Mann from the University of Edinburgh, LSST:UK Project Leader. “These exciting First Look images show that everything is working well and reassure us that we have a decade’s worth of wonderful data coming our way, with which UK astronomers will do great science.”

Hiranya Peiris is a Fellow of Murray Edwards College, Cambridge. 

The Vera C. Rubin Observatory, a new scientific facility that will bring the night sky to life like never before using the largest camera ever built, has revealed its ‘first look’ images at the start of its 10-year survey of the cosmos.

NSF-DOE Vera C. Rubin ObservatoryTrifid nebula (top right) and the Lagoon nebula

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Now, an international group of astronomers led by the University of Cambridge have shown that we will be able to learn about the masses of the earliest stars by studying a specific radio signal – created by hydrogen atoms filling the gaps between star-forming regions – originating just a hundred million years after the Big Bang.

By studying how the first stars and their remnants affected this signal, called the 21-centimetre signal, the researchers have shown that future radio telescopes will help us understand the very early universe, and how it transformed from a nearly homogeneous mass of mostly hydrogen to the incredible complexity we see today. Their results are reported in the journal Nature Astronomy.

“This is a unique opportunity to learn how the universe’s first light emerged from the darkness,” said co-author Professor Anastasia Fialkov from Cambridge’s Institute of Astronomy. “The transition from a cold, dark universe to one filled with stars is a story we’re only beginning to understand.”

The study of the universe’s most ancient stars hinges on the faint glow of the 21-centimetre signal, a subtle energy signal from over 13 billion years ago. This signal, influenced by the radiation from early stars and black holes, provides a rare window into the universe’s infancy.

Fialkov leads the theory group of REACH (the Radio Experiment for the Analysis of Cosmic Hydrogen). REACH is a radio antenna and is one of two major projects that could help us learn about the Cosmic Dawn and the Epoch of Reionisation, when the first stars reionised neutral hydrogen atoms in the universe.

Although REACH, which captures radio signals, is still in its calibration stage, it promises to reveal data about the early universe. Meanwhile, the Square Kilometre Array (SKA)—a massive array of antennas under construction—will map fluctuations in cosmic signals across vast regions of the sky.

Both projects are vital in probing the masses, luminosities, and distribution of the universe's earliest stars. In the current study, Fialkov – who is also a member of the SKA – and her collaborators developed a model that makes predictions for the 21-centimetre signal for both REACH and SKA, and found that the signal is sensitive to the masses of first stars.

“We are the first group to consistently model the dependence of the 21-centimetre signal of the masses of the first stars, including the impact of ultraviolet starlight and X-ray emissions from X-ray binaries produced when the first stars die,” said Fialkov, who is also a member of Cambridge’s Kavli Institute for Cosmology. “These insights are derived from simulations that integrate the primordial conditions of the universe, such as the hydrogen-helium composition produced by the Big Bang.”

In developing their theoretical model, the researchers studied how the 21-centimetre signal reacts to the mass distribution of the first stars, known as Population III stars. They found that previous studies have underestimated this connection as they did not account for the number and brightness of X-ray binaries – binary systems made of a normal star and a collapsed star – among Population III stars, and how they affect the 21-centimetre signal.

Unlike optical telescopes like the James Webb Space Telescope, which capture vivid images, radio astronomy relies on statistical analysis of faint signals. REACH and SKA will not be able to image individual stars, but will instead provide information about entire populations of stars, X-ray binary systems and galaxies.

“It takes a bit of imagination to connect radio data to the story of the first stars, but the implications are profound,” said Fialkov.

“The predictions we are reporting have huge implications for our understanding of the nature of the very first stars in the Universe,” said co-author Dr Eloy de Lera Acedo, Principal Investigator of the REACH telescope and PI at Cambridge of the SKA development activities. “We show evidence that our radio telescopes can tell us details about the mass of those first stars and how these early lights may have been very different from today’s stars.

“Radio telescopes like REACH are promising to unlock the mysteries of the infant Universe, and these predictions are essential to guide the radio observations we are doing from the Karoo, in South Africa.”

The research was supported in part by the Science and Technology Facilities Council (STFC), part of UK Research and Innovation (UKRI). Anastasia Fialkov is a Fellow of Magdalene College, Cambridge. Eloy de Lera Acedo is an STFC Ernest Rutherford Fellow and a Fellow of Selwyn College, Cambridge.

 

Reference:
T. Gessey-Jones et al. ‘Determination of the mass distribution of the first stars from the 21-cm signal.’ Nature Astronomy (2024). DOI: 10.1038/s41550-025-02575-x

Understanding how the universe transitioned from darkness to light with the formation of the first stars and galaxies is a key turning point in the universe’s development, known as the Cosmic Dawn. However, even with the most powerful telescopes, we can’t directly observe these earliest stars, so determining their properties is one of the biggest challenges in astronomy.

This is a unique opportunity to learn how the universe’s first light emerged from the darknessAnastasia FialkovESA/Webb, NASA, ESA, CSAThe image shows a deep galaxy field, featuring thousands of galaxies of various shapes and sizes

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution

Dr Alex Tsompanidis, senior researcher at the Autism Research Centre in the University of Cambridge, and the lead author of this new study, said: “Small variations in the prenatal levels of steroid hormones, like testosterone and oestrogen, can predict the rate of social and cognitive learning in infants and even the likelihood of conditions such as autism. This prompted us to consider their relevance for human evolution.”

One explanation for the evolution of the human brain may be in the way humans adapted to be social. Professor Robin Dunbar, an Evolutionary Biologist at the University of Oxford and joint senior author of this new study said: “We’ve known for a long time that living in larger, more complex social groups is associated with increases in the size of the brain. But we still don’t know what mechanisms may link these behavioural and physical adaptations in humans.”

In this new paper, published today in Evolutionary Anthropology, the researchers now propose that the mechanism may be found in prenatal sex steroid hormones, such as testosterone or oestrogens, and the way these affect the developing brain and behaviour in humans.

Using ‘mini-brains’ – clusters of human neuronal cells that are grown in a petri dish from donors’ stem cells – other scientists have been able to study, for the first time, the effects of these hormones on the human brain. Recent discoveries have shown that testosterone can increase the size of the brain, while oestrogens can improve the connectivity between neurons.

In both humans and other primates such as chimpanzees and gorillas, the placenta can link the mother’s and baby’s endocrine systems to produce these hormones in varying amounts.

Professor Graham Burton, Founding Director of the Loke Centre of Trophoblast Research at the University of Cambridge and coauthor of the new paper, said: “The placenta regulates the duration of the pregnancy and the supply of nutrients to the fetus, both of which are crucial for the development of our species’ characteristically large brains. But the advantage of human placentas over those of other primates has been less clear.”

Two previous studies show that levels of oestrogen during pregnancy are higher in human pregnancies than in other primate species.

Another characteristic of humans as a species is our ability to form and maintain large social groups, larger than other primates and other extinct species, such as Neanderthals. But to be able to do this, humans must have adapted in ways that maintain high levels of fertility, while also reducing competition in large groups for mates and resources.

Prenatal sex steroid hormones, such as testosterone and oestrogen, are also important for regulating the way males and females interact and develop, a process known as sex differentiation. For example, having higher testosterone relative to oestrogen leads to more male-like features in anatomy (e.g., in physical size and strength) and in behaviour (e.g., in competition).

But in humans, while these on-average sex differences exist, they are reduced, compared to our closest primate relatives and relative to other extinct human species (such as the Neanderthals). Instead, anatomical features that are specific to humans appear to be related more to aspects of female rather than male biology, and to the effects of oestrogens (e.g., reduced body hair, and a large ratio between the second and fourth digit).

The researchers propose that the key to explain this may lie again with the placenta, which rapidly turns testosterone to oestrogens, using an enzyme called aromatase. Recent discoveries show that humans have higher levels of aromatase compared to macaques, and that males may have slightly higher levels compared to females.

Bringing all these lines of evidence together, the authors propose that high levels of prenatal sex steroid hormones in the womb, combined with increased placental function, may have made human brains larger and more interconnected. At the same time, a lower ratio of androgens (like testosterone) to oestrogens may have led to reductions in competition between males, while also improving fertility in females, allowing humans to form larger, more cohesive social groups.

Professor Simon Baron-Cohen, Director of the Autism Research Centre at the University of Cambridge and joint senior author on the paper, said: “We have been studying the effects of prenatal sex steroids on neurodevelopment for the past 20 years. This has led to the discovery that prenatal sex steroids are important for neurodiversity in human populations. This new hypothesis takes this further in arguing that these hormones may have also shaped the evolution of the human brain.”

Dr Tsompanidis added: “Our hypothesis puts pregnancy at the heart of our story as a species. The human brain is remarkable and unique, but it does not develop in a vacuum. Adaptations in the placenta and the way it produces sex steroid hormones may have been crucial for our brain’s evolution, and for the emergence of the cognitive and social traits that make us human.”

Reference

Tsompanidis, A et al. The placental steroid hypothesis of human brain evolution. Evolutionary Anthropology; 20 June 2025; DOI: 10.1002/evan.70003

The placenta and the hormones it produces may have played a crucial role in the evolution of the human brain, while also leading to the behavioural traits that have made human societies able to thrive and expand, according to a new hypothesis proposed by researchers from the Universities of Cambridge and Oxford.

Our hypothesis puts pregnancy at the heart of our story as a speciesAlex TsompanidisNadzeya Haroshka (Getty Images)Models of a fetus in the womb and of the brain

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Representatives from Cambridge University Press & Assessment, Cambridge Zero, Cambridge Institute for Sustainability Leadership and Cambridge Judge Business School convened the session and were joined by a range of experts working on climate change-related research and education. Every speaker from across higher education highlighted the importance of identifying misinformation and disinformation in tackling climate action. Read more about the workshop here.

University of Cambridge experts highlighted the key role of education in combatting climate misinformation at a Global Sustainable Development Congress (GDSC) workshop in Turkey. Read about the GDSC workshop here

Photo of group at the conference in Turkey

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Today, all non-Africans are known to have descended from a small group of people that ventured into Eurasia around 50,000 years ago. However, fossil evidence shows that there were numerous failed dispersals before this time that left no detectable traces in living people.

In a new study published today in the journal in Nature, scientists say that from around 70,000 years ago, early humans began to exploit different habitat types in Africa in ways not seen before.

At this time, our ancestors started to live in the equatorial forests of West and Central Africa, and in the Sahara and Sahel desert regions of North Africa, where they encountered a range of new environmental conditions.

As they adapted to life in these diverse habitats, early humans gained the flexibility to tackle the range of novel environmental conditions they would encounter during their expansion out of Africa.

This increase in the human niche may have been the result of social adaptations, such as long-distance social networks, which allowed for an increase in cultural exchange. The process would have been self-reinforcing: as people started to inhabit a wider proportion of the African continent, regions previously disconnected would have come into contact, leading to further exchanges and possibly even greater flexibility. The final outcome was that our species became the ultimate generalist, able to tackle a wider range of environments.

Andrea Manica, Professor of Evolutionary Ecology in the University of Cambridge’s Department of Zoology, who co-led the study with Professor Eleanor Scerri from the Max Plank Institute of Bioanthropology in Germany, said: “Around 70,000-50,000 years ago, the easiest route out of Africa would have been more challenging than during previous periods, and yet this expansion was big - and ultimately successful.”

Manica added: “It’s incredibly exciting that we were able to look back in time and pinpoint the changes that enabled our ancestors to successfully migrate out of Africa.”

Dr Emily Hallett of Loyola University Chicago, co-lead author of the study, said: “We assembled a dataset of archaeological sites and environmental information covering the last 120,000 years in Africa. We used methods developed in ecology to understand changes in human environmental niches - the habitats humans can use and thrive in - during this time.” 

Dr Michela Leonardi at the University of Cambridge and London’s Natural History Museum, the study’s other lead author, said: “Our results showed that the human niche began to expand significantly from 70,000 years ago, and that this expansion was driven by humans increasing their use of diverse habitat types, from forests to arid deserts.” 

Many explanations for the uniquely successful dispersal out of Africa have previously been made, from technological innovations, to immunities granted by interbreeding with Eurasian hominins. But there is no evidence of technological innovation, and previous interbreeding does not appear to have helped the long-term success of previous attempts to spread out of Africa.

“Unlike previous humans dispersing out of Africa, those human groups moving into Eurasia after around 60-50,000 years ago were equipped with a distinctive ecological flexibility as a result of coping with climatically challenging habitats,” said Scerri. “This likely provided a key mechanism for the adaptive success of our species beyond their African homeland.”

Previous human dispersals out of Africa - which were not successful in the long term - seem to have happened during particularly favourable windows of increased rainfall in the Saharo-Arabian desert belt, which created ‘green corridors’ for people to move into Eurasia.

The environmental flexibility developed in Africa from around 70,000 years ago ultimately resulted in modern humans’ unique ability to adapt and thrive in diverse environments, and to cope with varying environmental conditions throughout life.

This research was supported by funding from the Max Planck Society, European Research Council and Leverhulme Trust.

Adapted from a press release by the Max Planck Institute of Geoanthropology, Germany

Reference: Hallett, E. Y. et al: ‘Major expansion in the human niche preceded out of Africa dispersal.’ Nature, June 2025. DOI: 10.1038/s41586-025-09154-0.

Before the ‘Out of Africa’ migration that led our ancestors into Eurasia and beyond, human populations learned to adapt to new and challenging habitats including African forests and deserts, which was key to the long-term success of our species’ dispersal.

It’s incredibly exciting that we were able to look back in time and pinpoint the changes that enabled our ancestors to successfully migrate out of Africa.Andrea ManicaOndrej Pelanek and Martin PelanekAfrican Bush Elephant

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution-Noncommerical

The successful Cambridge grantees’ work covers a range of research areas, including the development of next-generation semiconductors, new methods to identify dyslexia in young children, how diseases spread between humans and animals, and the early changes that happen in cells before breast cancer develops, with the goal of finding ways to stop the disease before it starts.

The funding, worth €721 million in total, will go to 281 leading researchers across Europe. The Advanced Grant competition is one of the most prestigious and competitive funding schemes in the EU and associated countries, including the UK. It gives senior researchers the opportunity to pursue ambitious, curiosity-driven projects that could lead to major scientific breakthroughs. Advanced Grants may be awarded up to € 2.5 million for a period of five years. The grants are part of the EU’s Horizon Europe programme. The UK agreed a deal to associate to Horizon Europe in September 2023.

This competition attracted 2,534 proposals, which were reviewed by panels of internationally renowned researchers. Over 11% of proposals were selected for funding. Estimates show that the grants will create approximately 2,700 jobs in the teams of new grantees. The new grantees will be based at universities and research centres in 23 EU Member States and associated countries, notably in the UK (56 grants), Germany (35), Italy (25), the Netherlands (24), and France (23).

“Many congratulations to our Cambridge colleagues on these prestigious ERC funding awards,” said Professor Sir John Aston, Cambridge’s Pro-Vice-Chancellor for Research. “This type of long-term funding is invaluable, allowing senior researchers the time and space to develop potential solutions for some of biggest challenges we face. We are so fortunate at Cambridge to have so many world-leading researchers across a range of disciplines, and I look forward to seeing the outcomes of their work.”

The Cambridge recipients of 2025 Advanced Grants are:

Professor Clare Bryant (Department of Veterinary Medicine) for investigating human and avian pattern recognition receptor activation of cell death pathways, and the impact on the host inflammatory response to zoonotic infections.

Professor Sir Richard Friend (Cavendish Laboratory/St John’s College) for bright high-spin molecular semiconductors.

Professor Usha Goswami (Department of Psychology/St John’s College) for a cross-language approach to the early identification of dyslexia and developmental language disorder using speech production measures with children.

Professor Regina Grafe (Faculty of History) for colonial credit and financial diversity in the Global South: Spanish America 1600-1820.

Professor Judy Hirst (MRC Mitochondrial Biology Unit/Corpus Christi College) for the energy-converting mechanism of a modular biomachine: Uniting structure and function to establish the engineering principles of respiratory complex I.

Professor Matthew Juniper (Department of Engineering/Trinity College) for adjoint-accelerated inference and optimisation methods.

Professor Walid Khaled (Department of Pharmacology/Magdalene College) for understanding precancerous changes in breast cancer for the development of therapeutic interceptions.

Professor Adrian Liston (Department of Pathology/St Catharine’s College) for dissecting the code for regulatory T cell entry into the tissues and differentiation into tissue-resident cells.

Professor Róisín Owens (Department of Chemical Engineering and Biotechnology/Newnham College) for conformal organic devices for electronic brain-gut readout and characterisation.

Professor Emma Rawlins (Department of Physiology, Development and Neuroscience/Gurdon Institute) for reprogramming lung epithelial cell lineages for regeneration.

Dr Marta Zlatic (Department of Zoology/Trinity College) for discovering the circuit and molecular basis of inter-strain and inter-species differences in learning

“These ERC grants are our commitment to making Europe the world’s hub for excellent research,” said Ekaterina Zaharieva, European Commissioner for Startups, Research, and Innovation. “By supporting projects that have the potential to redefine whole fields, we are not just investing in science but in the future prosperity and resilience of our continent. In the next competition rounds, scientists moving to Europe will receive even greater support in setting up their labs and research teams here. This is part of our “Choose Europe for Science” initiative, designed to attract and retain the world’s top scientists.”

“Much of this pioneering research will contribute to solving some of the most pressing challenges we face - social, economic and environmental,” said Professor Maria Leptin, President of the European Research Council. “Yet again, many scientists - around 260 - with ground-breaking ideas were rated as excellent, but remained unfunded due to a lack of funds at the ERC. We hope that more funding will be available in the future to support even more creative researchers in pursuing their scientific curiosity.”

Eleven senior researchers at the University of Cambridge have been awarded Advanced Grants from the European Research Council – the highest number of grants awarded to any institution in this latest funding round.

Westend61 via Getty ImagesScientist pipetting samples into eppendorf tube

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

In Invisible Rivals, published by Yale University Press today, Dr Goodman argues that throughout human history we have tried to rid our social groups of free-riders, people who take from others without giving anything back. But instead of eliminating free-riders, human evolution has just made them better at hiding their deception.

Goodman explains that humans have evolved to use language to disguise selfish acts and exploit our cooperative systems. He links this ‘invisible rivalry’ to the collapse of trust and consequent success of political strongmen today.

Goodman says: “We see this happening today, as evidenced by the rise of the Julius Caesar of our time—Donald Trump— but it is a situation that evolution has predicted since the origins of life and later, language, and which will only change form again even if the current crises are overcome.”

Goodman argues that over the course of human evolution “When we rid ourselves of ancient, dominant alphas, we traded overt selfishness for something perhaps even darker: the ability to move through society while planning and coordinating.”

“As much as we evolved to use language effectively to work together, to overthrow those brutish and nasty dominants that pervaded ancient society, we also (and do) use language to create opportunities that benefit us … We use language to keep our plans invisible. Humans, more than other known organisms, can cooperate until we imagine a way to compete, exploit, or coerce, and almost always rely on language to do so.”

Goodman, an expert on human social evolution at the University of Cambridge, identifies free-riding behaviour in everything from benefits cheating and tax evasion, to countries dodging action on climate change, and the actions of business leaders and politicians.

Goodman warns that “We can’t stop people free-riding, it’s part of our nature, the incurable syndrome… Free riders are among us at every level of society and pretending otherwise can make our own goals unrealistic, and worse, appear hopeless. But if we accept that we all have this ancient flaw, this ability to deceive ourselves and others, we can design policies around that and change our societies for the better.”

Lessons from our ancestors

Goodman points out that humans evolved in small groups meaning that over many generations we managed to design social norms to govern the distribution of food, water and other vital resources.

“People vied for power but these social norms helped to maintain a trend toward equality, balancing out our more selfish dispositions. Nevertheless, the free-rider problem persisted and using language we got better at hiding our cheating.”

One academic camp has argued that ancient humans used language to work together to overthrow and eject “brutish dominants”. The opposing view claims that this never happened and that humans are inherently selfish and tribal. Goodman rejects both extremes.

“If we accept the view that humans are fundamentally cooperative, we risk trusting blindly. If we believe everyone is selfish, we won’t trust anyone. We need to be realistic about human nature. We’re a bit of both so we need to learn how to place our trust discerningly.”

Goodman points out that our distant ancestors benefitted from risk-pooling systems, whereby all group members contributed labour and shared resources, but this only worked because it is difficult to hide tangible assets such as tools and food. While some hunter-gatherer societies continue to rely on these systems, they are ineffective in most modern societies in our globalized economy.

“Today most of us rely largely on intangible assets for monetary exchange so people can easily hide resources, misrepresent their means and invalidate the effectiveness of social norms around risk pooling,” Goodman says.

“We are flawed animals capable of deception, cruelty, and selfishness. The truth is hard to live with but confronting it through honest reflection about our evolutionary past gives us the tools to teach ourselves and others about how we can improve the future.”

Taking action: self-knowledge, education & policy

Goodman, who teaches students at Cambridge about the evolution of cooperation, argues that we reward liars from a young age and that this reinforces bad behaviour into adulthood.

“People tell children that cheaters don’t prosper, but in fact cheats who don’t get caught can do very well for themselves.”

“Evolutionarily speaking, appearing trustworthy but being selfish can be more beneficial to the individual. We need to recognise that and make a moral choice about whether we try to use people or to work with them.”

At the same time, Goodman thinks we need to arm ourselves intellectually with the power to tell who is credible and who is not. “Our most important tool for doing this is education,” he says. “We must teach people to think ethically for themselves, and to give them the tools to do so.”

But Goodman cautions that even the tools we use to expose exploiters are open to exploitation: “Think about how people across the political sphere accuse others of virtue signalling or abusing a well-intentioned political movement for their own gain.”

Goodman believes that exposing free-riders is more beneficial than punishment. “Loss of social capital through reputation is an important motivator for anyone,” he argues, suggesting that journalistic work exposing exploitation can be as effective at driving behaviour change as criminal punishment.

“The dilemma each of us faces now is whether to confront invisible rivalry or to let exploiters undermine society until democracy in the free world unravels—and the freedom of dissent is gone.”

Dr Jonathan R Goodman is a research associate at Cambridge Public Health and a social scientist at the Wellcome Sanger Institute.

Invisible Rivals: How We Evolved to Compete in a Cooperative World is published by Yale University Press on 17 June 2025 (ISBN: 9780300274356)

To save democracy and solve the world's biggest challenges, we need to get better at spotting and exposing people who exploit human cooperation for personal gain, argues Cambridge social scientist Dr Jonathan Goodman.

If we accept that we all have this ancient flaw, we can change our societies for the betterJonathan R GoodmanRalph via PixabayClose up of a handshake between two men wearing suits, with dollar bills in the background

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution

After winning a nail-biting East of England final, which was held as part of the Cambridge Festival in April 2025, Spatika went on to represent the East of England in the UK final with her presentation on Time Travel with Your Brain. She will now go on to represent the UK in the International Final taking place live at CERN Science Gateway in Switzerland to mark the 20 year anniversary of the competition. 

“I was so surprised I won!”, said Spatika. “The other communicators were fantastic and we travelled through so many topics from planets to parasites and more!”. 

Spatika took part in FameLab because she enjoyed talking about science to non-scientists and bringing some meaning to the complex work taking place in the labs. “I wanted a chance to bring humour into the science, because most of the times science is presented in professional environments, it’s all very serious”, added Spatika.  

“I would recommend FameLab for anyone who’s even a tiny bit interested in knowing what happens to science when it’s let out in the wild!” 

Claudia Antolini, Public Engagement Manager at the University of Cambridge said, “We are delighted for Spatika to represent the UK at the International FameLab final. Both at the East of England regional competition and the UK final Spatika gave outstanding performances, scientifically accurate but also extremely engaging with wise-cracking humour. We wish her the best of luck and we look forward to cheering her on for the International Final.” 

The FameLab final will be streamed live from CERN on YouTube. 

Spatika Jayaram is a PhD student and Gates Cambridge Scholar in the Department of Physiology, Development and Neuroscience and Magdalene College. In her research, she looks at social and emotional behaviours emerging across development, and how regions within the prefrontal cortex contribute to their regulation. 

FameLab was created by Cheltenham Festivals in 2005 and is the largest science communication competition and training programme in the world. Participants have just three minutes to convey a scientific concept of their choice to an audience and expert panel of judges with no presentations and limited props. 

Earlier this month, Cambridge PhD student Spatika Jayaram was crowned the winner of the FameLab 2025 UK final at this year’s Cheltenham Science Festival.  

Still Moving Media for Cheltenham Festivals

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes